While some studies have explored luliconazole for mild nail infections, this use is off-label and not approved by the MHRA. Discuss potential benefits and risks with a dermatologist before attempting nail treatment.
Luliconazole is classified as Category B in the UK, indicating that animal studies have not shown fetal risk but human data are limited. Use only if the potential benefit outweighs any possible risk, and always under medical supervision.
Initial relief of itching and redness may be noticed within a few days, but visible clearance of the infection generally requires 1-2 weeks of consistent daily application.
A rash could indicate an allergic reaction. Discontinue the cream immediately, wash the area with mild soap and water, and seek medical advice promptly.
Apply the cream only to the affected area and a narrow margin of surrounding healthy skin. Avoid excessive spreading onto large areas of intact skin to reduce irritation.
Yes. After applying the cream to the feet, allow it to dry completely before putting on socks or shoes. Occlusive footwear can trap moisture and diminish the antifungal effect.
Yes. Wash your hands thoroughly after each application to prevent accidental transfer of the medication to the eyes or mucous membranes.
Concurrent use of multiple topical antifungals is generally unnecessary and may increase the risk of skin irritation. Consult a healthcare professional before combining products.
Keep the tube tightly capped, store it at room temperature away from heat and direct light, and avoid exposing it to extreme temperatures.
Luliconazole is a topical antifungal and is not listed among prohibited substances by major sports governing bodies. However, athletes should verify current regulations with their sport’s anti-doping authority.
Luliconazole is the active ingredient in Luzu 1%, a topical antifungal formulation supplied in a 30 g tube. It belongs to the imidazole class of antifungal agents and is used to treat common superficial fungal infections of the skin. In the United Kingdom, Luzu is a prescription-only medicine (POM) authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).
Luliconazole belongs to the azole family of antifungals. Its primary action is the inhibition of the fungal enzyme lanosterol 14α-demethylase (CYP51), which is essential for the synthesis of ergosterol - a key component of the fungal cell membrane. By blocking ergosterol production, luliconazole compromises membrane integrity, leading to increased permeability and eventual fungal cell death.
Key pharmacologic points:
Luzu 1% is approved in the UK for the following dermatological fungal infections:
These conditions are caused primarily by dermatophyte fungi such as Trichophyton and Epidermophyton species. By targeting the fungal cell membrane, luliconazole effectively eradicates the pathogen and relieves symptoms such as scaling, redness, and itching.
Evidence from peer-reviewed studies suggests that luliconazole may have activity against onychomycosis (fungal nail infection). However, this indication is not approved by the MHRA for Luzu 1% and would be considered off-label.
These reactions are usually transient and resolve without intervention. If they persist, patients should inform their healthcare provider.
Because luliconazole’s systemic exposure is negligible, clinically significant drug-drug interactions are rare. Nonetheless, consider the following:
If a dose is missed, apply the cream as soon as remembered unless it is near the time of the next scheduled dose. Do not double the dose.
Because systemic absorption is minimal, overdose is unlikely. In the rare event of excessive topical application, rinse the area with water and seek medical advice if irritation persists.
Abrupt cessation is acceptable once the prescribed course is completed. For prolonged therapy (e.g., chronic tinea), a clinician may recommend a tapering schedule to minimise rebound infection.
This article provides educational information about Luzu 1% (luliconazole) and is not a substitute for professional medical advice. Treatment decisions, including the use of the medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
